Omeros OMER
NASDAQ OMER
$18.95 -0.16 (-0.84%)
At close: Sep 4, 2026 · 4:00 PM EDT

Omeros (OMER) Other Non-Current Liabilities (2021 - 2026)

Omeros (OMER) posted Other Non-Current Liabilities of $84.0 million for Q1 2026, down 46.54% sequentially from $157.2 million in Q4 2025, and up 1766.81% YoY from $4.5 million in Q1 2025.

Analysis

Omeros (OMER) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

Omeros has reported Other Non-Current Liabilities for 6 years, with the latest figure at $84.0 million in Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 1766.81% year-over-year to $84.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.0 million (up 1766.81% YoY) and the FY2025 annual result came in at $157.2 million, up 3391.91% from the prior year.
  • Other Non-Current Liabilities retreated to $84.0 million in Q1 2026 per OMER's latest filing, from $157.2 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $157.2 million in Q4 2025 and troughed at $444000.0 in Q4 2022.
  • A 5-year average of $17.1 million and a median of $2.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
  • The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities plunged 60.18% in 2022, then surged 3391.91% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $444000.0 in 2022, then surged by 370.27% to $2.1 million in 2023, then surged by 115.57% to $4.5 million in 2024, then soared by 3391.91% to $157.2 million in 2025, then sank by 46.54% to $84.0 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $84.0 million, $157.2 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Omeros 1.38 Bn 1.38 Bn 27.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 55.22 Mn
Mar 31, 2026 84.03 Mn
Dec 31, 2025 157.17 Mn
Sep 30, 2025 4.50 Mn
Jun 30, 2025 4.50 Mn
Mar 31, 2025 4.50 Mn
Dec 31, 2024 4.50 Mn
Sep 30, 2024 3.09 Mn
Jun 30, 2024 2.09 Mn
Mar 31, 2024 2.09 Mn
Dec 31, 2023 2.09 Mn
Jun 30, 2023 496,000.00
Mar 31, 2023 452,000.00
Dec 31, 2022 444,000.00
Sep 30, 2022 999,000.00
Jun 30, 2022 961,000.00
Mar 31, 2022 922,000.00
Dec 31, 2021 1.12 Mn